
News & opinion
First medical use claims in European patent applications
Must a compound be shown to be suitable for each disease for first medical use claims to be sufficiently disclosed in applications for European patents, asks Matthieu Boulard.
Abonnez-vous à notre newsletter mensuelle, riche en idées, actualités et événements à la pointe de la Propriété Intellectuelle.
Must a compound be shown to be suitable for each disease for first medical use claims to be sufficiently disclosed in applications for European patents, asks Matthieu Boulard.
On 15 September 2022, our experts discussed best practices for protecting 'non-traditional' trademarks in an increasingly innovative world. Register for our webinar recording to find out more.
When you choose to file a trademark registration can have a direct impact on its validity. Too soon and it could lapse for non-use; too late and it could be invalid. Sigolène Pellet discusses the key elements to consider when determining the right time to register a trademark.
On 8 June, the European Court of First Instance ruled on a dispute that has been ticking over between two famous companies for more than five years: the Californian Apple Inc and the Swiss watchmaker Swatch AG.